Liquidia (NASDAQ:LQDA) Price Target Raised to $110.00

Liquidia (NASDAQ:LQDA) had its price objective raised by Needham & Company LLC from $70.00 to $110.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also commented on LQDA. Piper Sandler set a $129.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Stephens set a $130.00 price target on Liquidia in a report on Friday, July 24th. HC Wainwright set a $36.00 price objective on Liquidia in a research note on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Liquidia in a research note on Monday, May 11th. Finally, BTIG Research upped their price objective on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $98.08.

Liquidia Trading Up 3.2%

NASDAQ LQDA opened at $74.44 on Wednesday. The firm’s fifty day moving average price is $78.67 and its 200 day moving average price is $55.13. Liquidia has a 12 month low of $21.15 and a 12 month high of $93.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.03. The company has a market capitalization of $6.62 billion, a price-to-earnings ratio of 54.34 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the previous year, the business posted ($0.49) EPS. The business’s revenue for the quarter was up 1842.1% compared to the same quarter last year. On average, sell-side analysts expect that Liquidia will post 2.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, Director Paul B. Manning sold 200,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the sale, the director owned 716,311 shares in the company, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the transaction, the director directly owned 1,176,184 shares of the company’s stock, valued at $82,838,639.12. The trade was a 17.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 1,756,861 shares of company stock valued at $122,981,112. Company insiders own 25.60% of the company’s stock.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia during the 4th quarter valued at about $25,000. NewEdge Advisors LLC acquired a new position in Liquidia during the second quarter valued at approximately $25,000. Covestor Ltd grew its stake in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after acquiring an additional 4,927 shares in the last quarter. Finally, Globeflex Capital L P acquired a new stake in shares of Liquidia in the second quarter worth $175,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).